Literature DB >> 5165782

Cholestyramine and nicotinic acid in the treatment of familial hyperbetalipoproteinaemia in the homozygous form.

C D Moutafis, N B Myant, M Mancini, P Oriente.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5165782     DOI： 10.1016/0021-9150(71)90054-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN： 0021-9150            Impact factor:   5.162


× No keyword cloud information.
  8 in total

Review 1.  Hyperlipidaemia in children.

Authors:  J K Lloyd
Journal:  Br Heart J       Date:  1975-02

Review 2.  Therapy of lipid disorders.

Authors:  D M Krikler
Journal:  J Clin Pathol Suppl (Assoc Clin Pathol)       Date:  1973

Review 3.  Lipid lowering drugs and hyperlipidaemia.

Authors:  R I Levy; B M Rifking
Journal:  Drugs       Date:  1973       Impact factor: 9.546

Review 4.  Hypolipaemic drugs and coronary heart disease.

Authors:  A N Howard
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1975

5.  Prevention of induced atherosclerosis by diversion of bile or blockade of intestinal lymphatics in dogs.

Authors:  P J Wilk; R C Karipineni; D Pertsemlidis; C A Danese
Journal:  Ann Surg       Date:  1976-04       Impact factor: 12.969

6.  [Drug treatment of primary hyperlipoproteinemia (author's transl)].

Authors:  G Klose; R Mordasini; G Middelhoff; J Augustin; H Greten
Journal:  Klin Wochenschr       Date:  1978-02-01

7.  A comparison of cholestyramine and nicotinic acid in the treatment of familial type II hyperlipoproteinaemia.

Authors:  J I Mann; P A Harding; R C Turner; R H Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

8.  Effects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination.

Authors:  H Gylling; H Vanhanen; T A Miettinen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.